Latest studies
- RecruitingPHASE3
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study is testing a new medicine, plozasiran, for people with very high triglycerides who have had pancreatitis. It will check if the medicine is safe and helps reduce the risk of future pancreatitis attacks. Participants will get either the study medicine or a dummy medicine.
Severe HypertriglyceridemiaLithuania - Not yet recruiting
Phase 3a and 3b update of the gastric cancer module, EORTC QLQ-STO22
Researchers are updating a widely used questionnaire that measures how stomach cancer and modern treatments affect daily life and well-being. If you have stomach cancer, you can help by completing the draft survey and sharing your feedback during a single, one-off chat lasting up to an hour.
Gastric adenocarcinomaLithuania - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)
This study is testing a new tablet called CRD-4730 for adults with heart failure. Researchers want to see if the medicine can help the heart pump blood better, ease everyday symptoms, and improve quality of life. Participants will take either the study drug or a dummy pill for 24 weeks.
heart failureLithuania - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy
This study tests a medicine called Vyvgart in adults with Sjögren's disease who have nerve damage in their hands, legs, or feet. Researchers want to see if regular injections under the skin can ease nerve symptoms, reduce fatigue, and be used safely compared with a dummy treatment.
Sjogren’s Disease-Associated Sensorimotor Polyneuropathy (SMPN) or Sensory Polyneuropathy (SPN)Lithuania - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, DoubleBlind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension (PALM-PAH)
This study is testing a new once-daily dry powder inhaler called treprostinil palmitil for pulmonary arterial hypertension (high blood pressure in the lungs). Doctors want to see if inhaling this medicine once a day helps people walk further and improves their daily symptoms compared with a dummy medicine (placebo).
Pulmonary Arterial HypertensionLithuania - RecruitingTherapeutic confirmatory (Phase III)
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study)
This Phase 3 clinical study tests a new injection called plozasiran for adults with very high blood fats, known as triglycerides. Researchers want to see if plozasiran can safely lower these fat levels over 12 months compared to a dummy jab, reducing the risk of painful pancreas inflammation.
Severe hypertriglyceridemia (SHTG)Lithuania - RecruitingPhase II and Phase III (Integrated)
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
This clinical trial is testing a new injection called efgartigimod for adults with inflammatory muscle disease (myositis). Researchers want to see if the medicine can safely reduce muscle inflammation, improve strength, and help people lower their daily steroid dose compared to a dummy treatment over 52 weeks.
Active Idiopathic Inflammatory Myopathy (IIM)Lithuania - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease
This study tests whether a medicine called efgartigimod can help adults with primary Sjögren’s disease. Researchers want to see if regular injections under the skin can ease symptoms like joint pain, dry eyes, and dry mouth, and lower overall body inflammation compared with a dummy treatment (placebo).
Primary Sjögren’s DiseaseLithuania - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, randomized, open-label, dose-finding study of Debio 4228, an extended-release formulation of gonadotropin-releasing hormone antagonist in participants with advanced prostate cancer
This Phase 2 trial tests a slow-release injection called Debio 4228 for men with advanced prostate cancer. The drug works by lowering testosterone, a hormone that fuels prostate cancer growth. Researchers want to find the safest and most effective dose, measure drug levels, and monitor side effects.
advanced prostate cancerLithuania - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy (PROTECT)
This phase 3 clinical study tests a new medicine called sparsentan for adults with IgA nephropathy, a serious kidney condition. Researchers want to see if sparsentan is better at reducing protein leaks in urine and protecting kidney function over time compared to a standard medicine called irbesartan.
Immunoglobulin A Nephropathy (IgAN)Lithuania - RecruitingTherapeutic confirmatory (Phase III)
A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination with Platinum-Pemetrexed Chemotherapy in Patients with Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
This study tests a new medicine called CT-P51 compared to an established treatment, Keytruda, for advanced non-small cell lung cancer. Both medicines are given with standard chemotherapy. The aim is to see if CT-P51 works just as well and is just as safe as Keytruda for newly diagnosed patients.
Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung CancerLithuania - RecruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients
This study tests a new medicine called FYB206 for adults who have had advanced skin cancer (melanoma) removed by surgery. Researchers want to check if FYB206 behaves in the body in the exact same way as Keytruda, an approved immunotherapy drug used to help stop cancer returning.
Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resectionLithuania - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
This phase 3 clinical trial is looking at a new combination of immunotherapy drugs given alongside chemotherapy. It aims to find out if this new combination helps people with untreated, advanced cancer of the stomach or food pipe live longer compared to the current standard immunotherapy and chemotherapy treatment.
Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric CancerLithuania - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia
This clinical trial looks at new treatments for adults with chronic lymphocytic leukaemia (CLL) who have not had treatment before. It compares a targeted drug called acalabrutinib, taken alone or with an antibody drip, against standard chemotherapy to find out which option controls leukaemia best and causes fewer side effects.
Chronic Lymphocytic LeukemiaLithuania - RecruitingTherapeutic confirmatory (Phase III)
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
This study looks at a new drug called nemolizumab for adults with moderate-to-severe eczema (atopic dermatitis). Researchers want to see how safe the medicine is when used over a long period. They also want to find out how well it clears skin, calms itchiness, and improves sleep.
Atopic DermatitisLithuania - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2420, a Growth Hormone Receptor Antagonist, Administered Subcutaneously in Combination with Somatostatin Analogs in Adult Participants with Acromegaly
This study tests a new injection called ALXN2420 for adults with acromegaly. Researchers want to see if adding it to usual hormone treatments helps lower a key body protein called IGF-1 more effectively, while checking its safety and side effects over 15 weeks of treatment.
AcromegalyLithuania - AuthorisedTherapeutic confirmatory (Phase III)
A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants with Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)
This clinical trial is testing new blood-thinning medicines for adults with peripheral artery disease who recently had a procedure to restore blood flow in their legs. Researchers want to find out if these medicines can prevent serious blood clots, heart attacks, and amputations without causing major bleeding problems.
Peripheral Artery DiseaseLithuania - RecruitingTherapeutic confirmatory (Phase III)
ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
The ZEUS study is looking at whether a new medicine called ziltivekimab can protect people with heart and kidney problems. Researchers want to see if lowering body swelling and inflammation can reduce the chances of serious health events like heart attacks, strokes, or worsening kidney disease.
Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammationLithuania - AuthorisedTherapeutic confirmatory (Phase III)
Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)
This phase 3 trial looks at whether an immunotherapy drug called durvalumab helps people with limited-stage small cell lung cancer live longer. It tests if giving durvalumab through a drip after standard chemotherapy and radiotherapy helps keep the cancer from returning.
Small-cell lung cancer, limited stageLithuania - RecruitingTherapeutic exploratory (Phase II)
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants with Relapsing Multiple Sclerosis
This study is looking into a new medicine, LY3541860, for people with relapsing multiple sclerosis (RMS). Researchers want to see if it can reduce the number of new spots on the brain (lesions) compared to a dummy treatment (placebo).
Relapsing Multiple SclerosisLithuania - RecruitingTherapeutic confirmatory (Phase III)
A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-induced Allergic Rhinoconjunctivitis with or without Asthma
This study is testing a new treatment called STALORAL® Birch for children and teenagers aged 5 to 17 who suffer from hay fever (allergic rhinoconjunctivitis) caused by birch pollen. It looks at how safe and effective the treatment is, and if it could help with asthma too.
Birch Pollen-induced Allergic RhinoconjunctivitisLithuania - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
This study is testing a new medicine, Tovinontrine, for people with a type of heart failure where the heart struggles to pump blood effectively. It aims to see if different doses are safe and if the medicine helps improve heart health over 12 weeks.
Heart failure (HF) with reduced ejection fraction (HFrEF)Lithuania - RecruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
SchizophreniaLithuania - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Open-label, Active-Control Study of REGN7508, a Factor XI Monoclonal Antibody, for the Prevention of Venous Thromboembolism in Participants Undergoing an Elective, Unilateral, Total Knee Arthroplasty (ROXI-VTE II)
This study is testing a new medicine, REGN7508, to prevent blood clots after knee replacement surgery. It compares the new medicine with a standard blood clot prevention medicine, Inhixa/Clexane, to see how well it works and if it causes side effects.
Thromboembolic diseaseLithuania - RecruitingPhase II and Phase III (Integrated)
Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS)
This study is looking at a new medicine called spesolimab for a skin condition called Hidradenitis Suppurativa, or HS. It's an extension study, meaning some people might have tried it before. Researchers want to see how safe and effective it is over a longer time.
Hidradenitis Suppurativa (HS)Lithuania - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid
This study is testing new combinations of medicines for a liver condition called Primary Biliary Cholangitis (PBC). We want to see if these combinations are safe and work better than current treatments, especially for people who haven't responded well to their usual medication.
Primary Biliary Cholangitis (PBC)Lithuania - RecruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
This study is looking at a new treatment for stomach cancer and cancer where the food pipe joins the stomach. It's comparing a drug called pembrolizumab combined with chemotherapy against chemotherapy alone, to see if it helps patients live longer and stops the cancer from coming back.
Gastric and gastroesophageal junction (GEJ) adenocarcinomaLithuania - RecruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo controlled, 2-armmulticenter phase 3 study to assess the efficacy and safetyof ianalumab in patients with active Sjögren’s syndrome(NEPTUNUS-1)
This study is testing a new medicine, ianalumab, for adults with active Sjögren’s syndrome. It compares the new medicine to a dummy medicine (placebo) to see if it helps reduce symptoms and improve quality of life.
Sjögren’s SyndromeLithuania - RecruitingTherapeutic confirmatory (Phase III)
A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with CAP including COVID-19 pneumonia.
This study is looking at a new treatment called trimodulin for adults in hospital with pneumonia, including pneumonia caused by COVID-19. Researchers want to see if it makes people better and is safe to use compared to a dummy treatment.
Non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19)Lithuania - RecruitingHuman Pharmacology (Phase I)- First administration to humans
An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in patients with solid tumors
This study is testing a new medicine, NECVAX-NEO1, alongside standard cancer treatments (like anti-PD-1 or anti-PD-L1 drugs). It's for people with certain solid tumours like lung cancer or melanoma. This early-stage trial aims to see if the new medicine is safe and how it works in the body.
Non-Small Cell Lung Cancer, cutaneous melanoma, urothelial cancer,renal cell cancer, Squamous Cell Carcinoma of the Head and NeckLithuania - RecruitingTherapeutic confirmatory (Phase III)
A phase 3, randomised, double-blind, placebo-controlled study assessing the efficacy and safety of gliclazide MR in patients with type 2 diabetes inadequately controlled with dapagliflozin with or without metformin.
This study looks at a medicine called gliclazide MR to see if it helps people with type 2 diabetes whose blood sugar isn't well controlled, even when using other common diabetes medicines like dapagliflozin or metformin. It aims to see if it's safe and effective.
Type 2 Diabetes inadequately controlled with dapagliflozin with or without metforminLithuania - RecruitingTherapeutic confirmatory (Phase III)
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®
This study is comparing a new medicine, JPB898, to a licensed cancer drug called Opdivo. Both are used with another drug, Yervoy, to treat advanced melanoma, a serious type of skin cancer. The aim is to see if JPB898 works just as well and is as safe as Opdivo.
Advanced (unresectable/metastatic) melanomaLithuania - RecruitingTherapeutic confirmatory (Phase III)
A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa
This study is looking at a medicine called secukinumab for people with moderate to severe hidradenitis suppurativa (HS). It aims to see how well the medicine works long-term and if it is safe, especially after people have already seen some improvement.
Hidradenitis suppurativaLithuania - RecruitingTherapeutic exploratory (Phase II)
Interventional, randomized, double-blind, parallel-group, placebo-controlled, dose-finding trial of Lu AG09222 for the prevention of migraine in participants with episodic and chronic migraine. Lundbeck trial no: 20297A
This study is testing a new medicine, Lu AG09222, to see if it can help prevent migraines. It's for people who get migraines often, including those with episodic (comes and goes) and chronic (very frequent) migraine. Researchers want to find the best dose to reduce migraine days.
MigraineLithuania - RecruitingTherapeutic exploratory (Phase II)
A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS906 in Patients with C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)
This study is testing a new medicine, OMS906, for certain kidney diseases. We want to see if it's safe, how it works in the body, and if it helps improve kidney function in people with C3G and ICGN conditions.
C3 Glomerulopathy and Idiopathic Immune Complex-Mediated GlomerulonephritisLithuania - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Parallel Group, Multicentre Study to Compare Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, immunogenicity, of BP11 versus EU-Approved Xolair in patients With Chronic Spontaneous Urticaria Who Are Resistant to H1 Antagonist.
This study compares a new medicine (BP11) with an approved one (Xolair) for chronic hives that haven't responded to usual treatments. Researchers want to see if BP11 is safe and effective in reducing itching and other symptoms.
Chronic UrticariaLithuania - RecruitingTherapeutic confirmatory (Phase III)
Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)
This study is looking into a new treatment called itepekimab for people with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). It will compare the new drug to a dummy treatment to see if it helps reduce flare-ups of COPD and improves lung function in former smokers.
Chronic Obstructive Pulmonary DiseaseLithuania - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
This study is testing a new treatment called OPT-302, given alongside an existing treatment (Eylea), for a serious eye condition called 'wet' Age-related Macular Degeneration (AMD). Doctors want to see if combining these treatments helps people see better than Eylea alone.
Neovascular Age-related Macular Degeneration (wet AMD)Lithuania - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, in Adults (OP0595-5)
This study is testing new medicines for serious urine infections. It compares them to a standard medicine to see if they are safe and work well for adults with complicated urine infections or kidney infections, checking if they clear the infection and make patients feel better.
Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)Lithuania - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcerative Colitis
This study is testing a new medicine, VTX002, for people with moderate to severe ulcerative colitis. Researchers want to see if it helps reduce symptoms and improve the condition, compared to a dummy pill.
Moderately to Severely Active Ulcerative ColitisLithuania - RecruitingTherapeutic exploratory (Phase II)
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)
This study looks at a new medicine called BH-200 for adults with severe depression. It compares BH-200 to a dummy pill to see if it helps improve mood and daily life better, and if it's safe.
Major Depressive DisorderLithuania - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)
This study is testing a new combination treatment for advanced ovarian, fallopian tube, or peritoneal cancers that haven't responded to previous chemotherapy. It compares a new drug, nemvaleukin alfa, with an existing cancer drug, pembrolizumab, against standard chemotherapy treatments to see if it helps people live longer.
Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerLithuania - RecruitingTherapeutic exploratory (Phase II)
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis
This study is looking at a new medicine called VE202 for people with mild to moderate ulcerative colitis. It aims to see if VE202 can help improve the condition and if it's safe to use compared to a dummy medicine.
Mild-to-moderate ulcerative colitisLithuania - RecruitingTherapeutic exploratory (Phase II)
First-line treatment with osimertinib in EGFR-mutated non-small cell lung cancer, coupled to extensive translational studies (The FIOL-study)
This study looks at a medicine called osimertinib (also known as Tagrisso) for a type of lung cancer with a specific gene change (EGFR mutation). We want to see how well it shrinks tumours and helps people live longer, while also checking if it's safe.
EGFR-mutated non-small cell lung cancerLithuania - RecruitingTherapeutic exploratory (Phase II)
CDX0159-07: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Chronic Inducible Urticaria
This study is testing a new medicine called Barzolvolimab for people with chronic inducible urticaria (hives that can be triggered). It aims to see if the medicine can stop hives from appearing when triggered by cold or scratching, and if it's safe to use.
Chronic Inducible UrticariaLithuania - RecruitingTherapeutic exploratory (Phase II)
A MULTICENTER, OPEN-LABEL, EVALUATOR-BLINDED, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SINGLE-DOSE INTRAVENOUS ORITAVANCIN FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
This study is looking at how safe a new medicine called Oritavancin (also known as ORBACTIV or KIMYRSA) is for children with serious skin infections. Researchers want to see if it causes any problems when given as a single dose through a drip.
Acute Bacterial Skin and Skin Structure InfectionsLithuania - RecruitingTherapeutic exploratory (Phase II)
Potential of FX06 to improve disease severity in Acute Respiratory Distress Syndrome patients (Ixion 2.0)
This study, called Ixion 2.0, is investigating a new treatment called FX06 for a severe lung condition called Acute Respiratory Distress Syndrome (ARDS). It aims to see if FX06 helps patients breathe on their own sooner compared to a dummy treatment.
Acute Respiratory Distress Syndrome (ARDS)Lithuania - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis
This study looks at a new drug combination for Primary Biliary Cholangitis (PBC). It checks if mixing two existing medicines, Obeticholic Acid and Bezafibrate, helps liver health over a long time. Researchers want to see how safe and effective this combination is for patients.
Primary Biliary Cholangitis (PBC)Lithuania - RecruitingTherapeutic confirmatory (Phase III)
TACTI-004, a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (PD-1 antagonist) and chemotherapy.
This study is testing a new combination of treatments for advanced lung cancer. It combines a new drug, eftilagimod alfa, with existing treatments like pembrolizumab and chemotherapy, to see if it can help people live longer and improve their quality of life. Participants will be randomly assigned to different treatment groups.
Advanced/metastatic non-small cell lung cancer (NSCLC)Lithuania - RecruitingPHASE3
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This study looks at new ways to treat high-risk neuroblastoma, a type of cancer, in children and young people. Researchers are testing different combinations of chemotherapy and radiation to find the most effective treatments to help patients live longer and healthier lives.
High-Risk NeuroblastomaPatient With Insufficient Response ChemoimmunotherapyLithuania